Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Cure8 research brief
Why This Matters
Ulcerative colitis changes the colonic environment in ways that can make current mesalazine formulations release unpredictably. New delivery approaches aimed at stabilising drug interfaces could lead to more consistent local drug exposure and potentially better symptom control.
Who Should Pay Attention
Researchers (drug formulation, pharmacology), clinicians interested in IBD therapeutics, and drug-development teams working on colonic delivery systems.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review looks at problems with ‘‘trigger-dependent’’ mesalazine (mesalamine) oral formulations in ulcerative colitis and evaluates an alternative: polymer-stabilised nano-co-crystals that control drug behaviour at the formulation–mucus and solid–liquid interfaces rather than relying on pH, enzymes, or inflammation cues.
The authors argue that active UC causes fluctuating luminal pH, altered transit, mucus remodelling, oxidative stress, and microbiota changes that can make trigger-responsive release unreliable.
They describe how polymer adsorption onto nano-co-crystal surfaces can stabilise crystals, moderate dissolution, suppress aggregation/recrystallisation, maintain supersaturation, and potentially improve interaction with inflammation-modified mucus to prolong mucosal residence and reduce washout.
This is a mechanistic, formulation-focused review framing colonic delivery as an interface engineering problem and proposing polymer-stabilised nano-co-crystals as a trigger-independent design rationale to explore further. It does not report patient-level clinical outcomes.
Keep In Mind
This is a mechanistic/formulation review (abstract-level source). It proposes polymer-stabilised nano-co-crystals as a concept and summarizes preclinical rationale; it does not provide clinical trial data or definitive evidence of patient benefit.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
AuthorsArif Khan, Sandeep Kumar, Anil Rajnath Singh +3 more
InstitutionDepartment of Pharmaceutics, NIMS Institute of Pharmacy, Rajasthan, India.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedSep 10, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Microenvironment-adaptive drug delivery systems for ulcerative colitis: from pathological constraints to rational design.
The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...
Transient receptor potential vanilloid channels in inflammatory bowel diseases: linking inflammation, angiogenesis, and oxidative stress.
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
Nanomaterial-based modulation of inflammatory and cytokine networks for precision therapy in inflammatory bowel disease.
Nanotechnology approaches aim to improve how cytokine-targeting therapies are delivered in IBD, which could reduce systemic exposure and immunogenicity and increase local effectiveness.